Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RO7486967
Selnoflast · 2 trials · 2 indications
hsCRP=high-sensitivity C-reactive protein.
| Arm | Type | Description |
|---|---|---|
| Selnoflast | EXPERIMENTAL | Participants will receive selnoflast, orally (PO), twice a day (BID) for 12 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo, PO, BID for 12 weeks. |
| RO7486967 Arm | EXPERIMENTAL | Participants will receive RO07486967 for approximately 28 days with 14 days of follow up after the last dose. |
| Name | Type | Description |
|---|---|---|
| Selnoflast | DRUG | Selnoflast will be administered as per the schedule specified in the respective arm. |
| Placebo | DRUG | Placebo will be administered as per the schedule specified in the respective arm. |
| RO7486967 | DRUG | For up to approximately 28 days |
Inclusion Criteria: * Confirmed evidence of atherosclerosis * Left or right carotid TBR ≥ 1.8 or aorta TBR ≥ 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan * Stable treatment of atherosclerosis through the use of SOC medications or revascularization...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
Selnoflast is an investigational small molecule being developed for the treatment of atherosclerosis, a cardiovascular condition characterized by the buildup of plaque in the arteries. It is intended for use in patients with atherosclerosis who are at risk for major adverse cardiac events, as part of a Phase 2 clinical trial.
Selnoflast is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is currently conducting a Phase 2 clinical trial to evaluate the drug's efficacy and safety in patients with atherosclerosis.
Selnoflast is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to study its effects in reducing vascular inflammation in atherosclerosis.
Selnoflast is being studied in a single Phase 2 clinical trial with the identifier NCT07448038. This randomized, double-blind, placebo-controlled trial is recruiting 162 participants in the United States and Canada to evaluate the drug's efficacy, safety, pharmacodynamics, and pharmacokinetics in reducing vascular inflammation in atherosclerosis.
Selnoflast is a small molecule designed to reduce vascular inflammation in patients with atherosclerosis. The exact molecular target of Selnoflast has not been disclosed in the available information, so its specific mechanism of action is not detailed here.